nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGER4—Crohn's disease	0.0112	0.0399	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—CCR9—Crohn's disease	0.00933	0.0332	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGER4—Crohn's disease	0.00802	0.0286	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.00668	0.0238	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—CCR9—Crohn's disease	0.00668	0.0238	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—MLN—Crohn's disease	0.00641	0.0228	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—MLN—Crohn's disease	0.00633	0.0225	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—CCR6—Crohn's disease	0.00618	0.022	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.00574	0.0204	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.00523	0.0186	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.00478	0.017	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—MLN—Crohn's disease	0.00459	0.0163	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—MLN—Crohn's disease	0.00453	0.0161	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00448	0.0159	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—CCR6—Crohn's disease	0.00442	0.0158	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.00439	0.0156	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00425	0.0151	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—Crohn's disease	0.00423	0.0151	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—GPR65—Crohn's disease	0.00413	0.0147	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.0041	0.0146	CbGpPWpGaD
Sitaxentan—Metrorrhagia—Mesalazine—Crohn's disease	0.00388	0.0054	CcSEcCtD
Sitaxentan—Blood potassium decreased—Prednisone—Crohn's disease	0.00386	0.00537	CcSEcCtD
Sitaxentan—Tongue disorder—Mesalazine—Crohn's disease	0.00381	0.0053	CcSEcCtD
Sitaxentan—Dermatitis atopic—Mesalazine—Crohn's disease	0.00375	0.00521	CcSEcCtD
Sitaxentan—Menorrhagia—Mesalazine—Crohn's disease	0.00375	0.00521	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.00374	0.0133	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.0037	0.0132	CbGpPWpGaD
Sitaxentan—Cholestasis—Mesalazine—Crohn's disease	0.00365	0.00508	CcSEcCtD
Sitaxentan—Tubulointerstitial nephritis—Mesalazine—Crohn's disease	0.00362	0.00504	CcSEcCtD
Sitaxentan—Pleural effusion—Mesalazine—Crohn's disease	0.00362	0.00504	CcSEcCtD
Sitaxentan—Feeling hot—Mesalazine—Crohn's disease	0.00353	0.00491	CcSEcCtD
Sitaxentan—Hyperaesthesia—Mesalazine—Crohn's disease	0.00353	0.00491	CcSEcCtD
Sitaxentan—Rash pustular—Mesalazine—Crohn's disease	0.00348	0.00483	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00344	0.0122	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—ACKR2—Crohn's disease	0.00341	0.0121	CbGpPWpGaD
Sitaxentan—Breast disorder—Mercaptopurine—Crohn's disease	0.00335	0.00466	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—MLN—Crohn's disease	0.00323	0.0115	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00321	0.0114	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00319	0.0114	CbGpPWpGaD
Sitaxentan—Breast pain—Mesalazine—Crohn's disease	0.00318	0.00442	CcSEcCtD
Sitaxentan—Pancreatitis acute—Prednisone—Crohn's disease	0.00318	0.00442	CcSEcCtD
Sitaxentan—Proteinuria—Mesalazine—Crohn's disease	0.00316	0.00439	CcSEcCtD
Sitaxentan—Amenorrhoea—Mesalazine—Crohn's disease	0.00316	0.00439	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.00314	0.0112	CbGpPWpGaD
Sitaxentan—Protein urine present—Mesalazine—Crohn's disease	0.00311	0.00433	CcSEcCtD
Sitaxentan—Musculoskeletal stiffness—Mesalazine—Crohn's disease	0.00309	0.0043	CcSEcCtD
Sitaxentan—Endophthalmitis—Prednisone—Crohn's disease	0.00308	0.00428	CcSEcCtD
Sitaxentan—Pancytopenia—Mercaptopurine—Crohn's disease	0.00304	0.00423	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00304	0.0108	CbGpPWpGaD
Sitaxentan—Hypocalcaemia—Mesalazine—Crohn's disease	0.00303	0.00421	CcSEcCtD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—Crohn's disease	0.00303	0.0108	CbGpPWpGaD
Sitaxentan—Gout—Mesalazine—Crohn's disease	0.00297	0.00413	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—GPR65—Crohn's disease	0.00296	0.0105	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00294	0.0105	CbGpPWpGaD
Sitaxentan—Hepatic enzyme increased—Mesalazine—Crohn's disease	0.00293	0.00408	CcSEcCtD
Sitaxentan—Blood bilirubin increased—Mesalazine—Crohn's disease	0.00293	0.00408	CcSEcCtD
Sitaxentan—Colitis—Azathioprine—Crohn's disease	0.00292	0.00406	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00291	0.0104	CbGpPWpGaD
Sitaxentan—Musculoskeletal pain—Mesalazine—Crohn's disease	0.00281	0.0039	CcSEcCtD
Sitaxentan—Hypernatraemia—Prednisone—Crohn's disease	0.00279	0.00388	CcSEcCtD
Sitaxentan—Stomatitis—Mercaptopurine—Crohn's disease	0.00279	0.00387	CcSEcCtD
Sitaxentan—Neoplasm—Azathioprine—Crohn's disease	0.00275	0.00383	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00274	0.00974	CbGpPWpGaD
Sitaxentan—Eructation—Mesalazine—Crohn's disease	0.00272	0.00379	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.0027	0.00376	CcSEcCtD
Sitaxentan—Colitis—Mesalazine—Crohn's disease	0.00266	0.0037	CcSEcCtD
Sitaxentan—Candida infection—Mesalazine—Crohn's disease	0.00265	0.00368	CcSEcCtD
Sitaxentan—Skin exfoliation—Mesalazine—Crohn's disease	0.00265	0.00368	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.00265	0.00942	CbGpPWpGaD
Sitaxentan—Vaginal infection—Mesalazine—Crohn's disease	0.00262	0.00364	CcSEcCtD
Sitaxentan—Dry eye—Mesalazine—Crohn's disease	0.00256	0.00356	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—JAK2—Crohn's disease	0.00248	0.00884	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00246	0.00875	CbGpPWpGaD
Sitaxentan—Hepatic failure—Azathioprine—Crohn's disease	0.00246	0.00342	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—ACKR2—Crohn's disease	0.00244	0.00869	CbGpPWpGaD
Sitaxentan—Ear pain—Mesalazine—Crohn's disease	0.00236	0.00328	CcSEcCtD
Sitaxentan—Immune system disorder—Mercaptopurine—Crohn's disease	0.00232	0.00322	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—MLN—Crohn's disease	0.00231	0.00824	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00229	0.00814	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00228	0.0081	CbGpPWpGaD
Sitaxentan—Gastroenteritis—Mesalazine—Crohn's disease	0.00227	0.00316	CcSEcCtD
Sitaxentan—Alopecia—Mercaptopurine—Crohn's disease	0.00227	0.00315	CcSEcCtD
Sitaxentan—Deafness—Mesalazine—Crohn's disease	0.00225	0.00313	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—CCR9—Crohn's disease	0.00224	0.00798	CbGpPWpGaD
Sitaxentan—Hepatic failure—Mesalazine—Crohn's disease	0.00224	0.00311	CcSEcCtD
Sitaxentan—Malnutrition—Mercaptopurine—Crohn's disease	0.00223	0.00311	CcSEcCtD
Sitaxentan—Peptic ulcer—Prednisone—Crohn's disease	0.00219	0.00305	CcSEcCtD
Sitaxentan—Increased appetite—Mesalazine—Crohn's disease	0.00214	0.00298	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.00214	0.0076	CbGpPWpGaD
Sitaxentan—Renal impairment—Mesalazine—Crohn's disease	0.00211	0.00294	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00211	0.0075	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GPR65—Crohn's disease	0.00208	0.00742	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00208	0.00741	CbGpPWpGaD
Sitaxentan—Hepatomegaly—Prednisone—Crohn's disease	0.00207	0.00288	CcSEcCtD
Sitaxentan—Arthritis—Mesalazine—Crohn's disease	0.00207	0.00288	CcSEcCtD
Sitaxentan—Anaemia—Mercaptopurine—Crohn's disease	0.00206	0.00287	CcSEcCtD
Sitaxentan—Osteoarthritis—Mesalazine—Crohn's disease	0.00201	0.0028	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.00201	0.0028	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.002	0.00713	CbGpPWpGaD
Sitaxentan—Leukopenia—Mercaptopurine—Crohn's disease	0.002	0.00278	CcSEcCtD
Sitaxentan—Dermatitis atopic—Prednisone—Crohn's disease	0.00198	0.00276	CcSEcCtD
Sitaxentan—Migraine—Mesalazine—Crohn's disease	0.00198	0.00276	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00196	0.00697	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00195	0.00694	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00191	0.0068	CbGpPWpGaD
Sitaxentan—Fungal infection—Prednisone—Crohn's disease	0.0019	0.00264	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00189	0.00263	CcSEcCtD
Sitaxentan—Blood creatinine increased—Mesalazine—Crohn's disease	0.00189	0.00262	CcSEcCtD
Sitaxentan—Memory impairment—Prednisone—Crohn's disease	0.00187	0.0026	CcSEcCtD
Sitaxentan—Liver function test abnormal—Mesalazine—Crohn's disease	0.00186	0.00258	CcSEcCtD
Sitaxentan—Abscess—Prednisone—Crohn's disease	0.00185	0.00258	CcSEcCtD
Sitaxentan—Dry skin—Mesalazine—Crohn's disease	0.00184	0.00257	CcSEcCtD
Sitaxentan—Abdominal pain upper—Mesalazine—Crohn's disease	0.00184	0.00256	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Mesalazine—Crohn's disease	0.00184	0.00256	CcSEcCtD
Sitaxentan—Abdominal discomfort—Azathioprine—Crohn's disease	0.00183	0.00255	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—MLN—Crohn's disease	0.00183	0.00651	CbGpPWpGaD
Sitaxentan—Oedema—Mercaptopurine—Crohn's disease	0.00182	0.00253	CcSEcCtD
Sitaxentan—Breast disorder—Mesalazine—Crohn's disease	0.00182	0.00253	CcSEcCtD
Sitaxentan—Pancytopenia—Azathioprine—Crohn's disease	0.00181	0.00252	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00181	0.00252	CcSEcCtD
Sitaxentan—Cramp muscle—Mesalazine—Crohn's disease	0.00181	0.00252	CcSEcCtD
Sitaxentan—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00178	0.00248	CcSEcCtD
Sitaxentan—Petechiae—Prednisone—Crohn's disease	0.00178	0.00248	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—JAK2—Crohn's disease	0.00178	0.00633	CbGpPWpGaD
Sitaxentan—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00178	0.00247	CcSEcCtD
Sitaxentan—Skin disorder—Mercaptopurine—Crohn's disease	0.00177	0.00246	CcSEcCtD
Sitaxentan—Endocrine disorder—Prednisone—Crohn's disease	0.00177	0.00246	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00176	0.00628	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—ACKR2—Crohn's disease	0.00175	0.00623	CbGpPWpGaD
Sitaxentan—Asthma—Mesalazine—Crohn's disease	0.00174	0.00242	CcSEcCtD
Sitaxentan—Anorexia—Mercaptopurine—Crohn's disease	0.00174	0.00242	CcSEcCtD
Sitaxentan—Eosinophilia—Mesalazine—Crohn's disease	0.00172	0.0024	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00172	0.00611	CbGpPWpGaD
Sitaxentan—Infestation—Azathioprine—Crohn's disease	0.0017	0.00237	CcSEcCtD
Sitaxentan—Infestation NOS—Azathioprine—Crohn's disease	0.0017	0.00237	CcSEcCtD
Sitaxentan—Angina pectoris—Mesalazine—Crohn's disease	0.00169	0.00236	CcSEcCtD
Sitaxentan—Contusion—Prednisone—Crohn's disease	0.00168	0.00234	CcSEcCtD
Sitaxentan—Bronchitis—Mesalazine—Crohn's disease	0.00167	0.00233	CcSEcCtD
Sitaxentan—Amenorrhoea—Prednisone—Crohn's disease	0.00167	0.00232	CcSEcCtD
Sitaxentan—Abdominal discomfort—Mesalazine—Crohn's disease	0.00167	0.00232	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—MLN—Crohn's disease	0.00166	0.00591	CbGpPWpGaD
Sitaxentan—Pancytopenia—Mesalazine—Crohn's disease	0.00165	0.0023	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00163	0.0058	CbGpPWpGaD
Sitaxentan—Dysuria—Mesalazine—Crohn's disease	0.00163	0.00226	CcSEcCtD
Sitaxentan—Viral infection—Prednisone—Crohn's disease	0.00162	0.00226	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Azathioprine—Crohn's disease	0.00161	0.00224	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00161	0.00573	CbGpPWpGaD
Sitaxentan—Pollakiuria—Mesalazine—Crohn's disease	0.00161	0.00223	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CCR9—Crohn's disease	0.0016	0.00571	CbGpPWpGaD
Sitaxentan—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00159	0.00221	CcSEcCtD
Sitaxentan—Decreased appetite—Mercaptopurine—Crohn's disease	0.00158	0.0022	CcSEcCtD
Sitaxentan—Weight decreased—Mesalazine—Crohn's disease	0.00157	0.00219	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00157	0.00219	CcSEcCtD
Sitaxentan—Infestation NOS—Mesalazine—Crohn's disease	0.00155	0.00216	CcSEcCtD
Sitaxentan—Infestation—Mesalazine—Crohn's disease	0.00155	0.00216	CcSEcCtD
Sitaxentan—Hypercholesterolaemia—Prednisone—Crohn's disease	0.00155	0.00216	CcSEcCtD
Sitaxentan—Haemoglobin—Azathioprine—Crohn's disease	0.00154	0.00214	CcSEcCtD
Sitaxentan—Haemorrhage—Azathioprine—Crohn's disease	0.00153	0.00213	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.00153	0.00544	CbGpPWpGaD
Sitaxentan—Renal failure—Mesalazine—Crohn's disease	0.00152	0.00212	CcSEcCtD
Sitaxentan—Jaundice—Mesalazine—Crohn's disease	0.00151	0.0021	CcSEcCtD
Sitaxentan—Stomatitis—Mesalazine—Crohn's disease	0.00151	0.0021	CcSEcCtD
Sitaxentan—Conjunctivitis—Mesalazine—Crohn's disease	0.00151	0.0021	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—GPR65—Crohn's disease	0.00149	0.00531	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCR6—Crohn's disease	0.00149	0.00529	CbGpPWpGaD
Sitaxentan—Haematuria—Mesalazine—Crohn's disease	0.00148	0.00206	CcSEcCtD
Sitaxentan—Hiccups—Prednisone—Crohn's disease	0.00147	0.00204	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Mesalazine—Crohn's disease	0.00147	0.00204	CcSEcCtD
Sitaxentan—Epistaxis—Mesalazine—Crohn's disease	0.00146	0.00203	CcSEcCtD
Sitaxentan—Sinusitis—Mesalazine—Crohn's disease	0.00146	0.00202	CcSEcCtD
Sitaxentan—Body temperature increased—Mercaptopurine—Crohn's disease	0.00144	0.002	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00143	0.00511	CbGpPWpGaD
Sitaxentan—Skin exfoliation—Prednisone—Crohn's disease	0.0014	0.00195	CcSEcCtD
Sitaxentan—Haemoglobin—Mesalazine—Crohn's disease	0.0014	0.00195	CcSEcCtD
Sitaxentan—Rhinitis—Mesalazine—Crohn's disease	0.0014	0.00194	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.0014	0.00497	CbGpPWpGaD
Sitaxentan—Fluid retention—Prednisone—Crohn's disease	0.00139	0.00194	CcSEcCtD
Sitaxentan—Hepatitis—Mesalazine—Crohn's disease	0.00139	0.00194	CcSEcCtD
Sitaxentan—Haemorrhage—Mesalazine—Crohn's disease	0.00139	0.00194	CcSEcCtD
Sitaxentan—Immune system disorder—Azathioprine—Crohn's disease	0.00138	0.00192	CcSEcCtD
Sitaxentan—Mediastinal disorder—Azathioprine—Crohn's disease	0.00138	0.00192	CcSEcCtD
Sitaxentan—Urinary tract disorder—Mesalazine—Crohn's disease	0.00138	0.00191	CcSEcCtD
Sitaxentan—Oedema peripheral—Mesalazine—Crohn's disease	0.00137	0.00191	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00137	0.00487	CbGpPWpGaD
Sitaxentan—Urethral disorder—Mesalazine—Crohn's disease	0.00136	0.0019	CcSEcCtD
Sitaxentan—Alopecia—Azathioprine—Crohn's disease	0.00135	0.00188	CcSEcCtD
Sitaxentan—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00134	0.00187	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—MLN—Crohn's disease	0.00131	0.00466	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—PTGER4—Crohn's disease	0.00131	0.00465	CbGpPWpGaD
Sitaxentan—Eye disorder—Mesalazine—Crohn's disease	0.0013	0.00181	CcSEcCtD
Sitaxentan—Tinnitus—Mesalazine—Crohn's disease	0.0013	0.00181	CcSEcCtD
Sitaxentan—Cardiac disorder—Mesalazine—Crohn's disease	0.00129	0.0018	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR9—Crohn's disease	0.00127	0.00451	CbGpPWpGaD
Sitaxentan—Angiopathy—Mesalazine—Crohn's disease	0.00126	0.00176	CcSEcCtD
Sitaxentan—Immune system disorder—Mesalazine—Crohn's disease	0.00126	0.00175	CcSEcCtD
Sitaxentan—Mediastinal disorder—Mesalazine—Crohn's disease	0.00125	0.00175	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—ACKR2—Crohn's disease	0.00125	0.00446	CbGpPWpGaD
Sitaxentan—Diarrhoea—Mercaptopurine—Crohn's disease	0.00125	0.00173	CcSEcCtD
Sitaxentan—Ill-defined disorder—Azathioprine—Crohn's disease	0.00123	0.00172	CcSEcCtD
Sitaxentan—Alopecia—Mesalazine—Crohn's disease	0.00123	0.00171	CcSEcCtD
Sitaxentan—Anaemia—Azathioprine—Crohn's disease	0.00123	0.00171	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00123	0.00437	CbGpPWpGaD
Sitaxentan—Mental disorder—Mesalazine—Crohn's disease	0.00122	0.0017	CcSEcCtD
Sitaxentan—Malaise—Azathioprine—Crohn's disease	0.0012	0.00167	CcSEcCtD
Sitaxentan—Leukopenia—Azathioprine—Crohn's disease	0.00119	0.00166	CcSEcCtD
Sitaxentan—Tension—Mesalazine—Crohn's disease	0.00119	0.00165	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—MLN—Crohn's disease	0.00119	0.00423	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GPR65—Crohn's disease	0.00118	0.00419	CbGpPWpGaD
Sitaxentan—Nervousness—Mesalazine—Crohn's disease	0.00118	0.00164	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Prednisone—Crohn's disease	0.00117	0.00163	CcSEcCtD
Sitaxentan—Muscle spasms—Mesalazine—Crohn's disease	0.00117	0.00162	CcSEcCtD
Sitaxentan—Vomiting—Mercaptopurine—Crohn's disease	0.00116	0.00161	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CCR9—Crohn's disease	0.00115	0.0041	CbGpPWpGaD
Sitaxentan—Rash—Mercaptopurine—Crohn's disease	0.00115	0.0016	CcSEcCtD
Sitaxentan—Dermatitis—Mercaptopurine—Crohn's disease	0.00115	0.0016	CcSEcCtD
Sitaxentan—Tremor—Mesalazine—Crohn's disease	0.00114	0.00158	CcSEcCtD
Sitaxentan—Increased appetite—Prednisone—Crohn's disease	0.00113	0.00158	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00113	0.00156	CcSEcCtD
Sitaxentan—Ill-defined disorder—Mesalazine—Crohn's disease	0.00112	0.00156	CcSEcCtD
Sitaxentan—Anaemia—Mesalazine—Crohn's disease	0.00112	0.00156	CcSEcCtD
Sitaxentan—Discomfort—Azathioprine—Crohn's disease	0.00112	0.00156	CcSEcCtD
Sitaxentan—Malaise—Mesalazine—Crohn's disease	0.00109	0.00152	CcSEcCtD
Sitaxentan—Cardiac failure—Prednisone—Crohn's disease	0.00109	0.00152	CcSEcCtD
Sitaxentan—Vertigo—Mesalazine—Crohn's disease	0.00109	0.00151	CcSEcCtD
Sitaxentan—Leukopenia—Mesalazine—Crohn's disease	0.00109	0.00151	CcSEcCtD
Sitaxentan—Nausea—Mercaptopurine—Crohn's disease	0.00108	0.00151	CcSEcCtD
Sitaxentan—Infection—Azathioprine—Crohn's disease	0.00108	0.0015	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—GPR65—Crohn's disease	0.00107	0.00381	CbGpPWpGaD
Sitaxentan—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.00106	0.00148	CcSEcCtD
Sitaxentan—Osteoarthritis—Prednisone—Crohn's disease	0.00106	0.00148	CcSEcCtD
Sitaxentan—Thrombocytopenia—Azathioprine—Crohn's disease	0.00106	0.00148	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CCR6—Crohn's disease	0.00106	0.00378	CbGpPWpGaD
Sitaxentan—Skin disorder—Azathioprine—Crohn's disease	0.00105	0.00147	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—ACKR2—Crohn's disease	0.00103	0.00368	CbGpPWpGaD
Sitaxentan—Chest pain—Mesalazine—Crohn's disease	0.00103	0.00144	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00102	0.00143	CcSEcCtD
Sitaxentan—Discomfort—Mesalazine—Crohn's disease	0.00102	0.00142	CcSEcCtD
Sitaxentan—Hypotension—Azathioprine—Crohn's disease	0.00101	0.00141	CcSEcCtD
Sitaxentan—Dry mouth—Mesalazine—Crohn's disease	0.00101	0.0014	CcSEcCtD
Sitaxentan—Confusional state—Mesalazine—Crohn's disease	0.000998	0.00139	CcSEcCtD
Sitaxentan—Oedema—Mesalazine—Crohn's disease	0.000989	0.00138	CcSEcCtD
Sitaxentan—Infection—Mesalazine—Crohn's disease	0.000983	0.00137	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—MLN—Crohn's disease	0.00098	0.00349	CbGpPWpGaD
Sitaxentan—Dry skin—Prednisone—Crohn's disease	0.000976	0.00136	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000975	0.00347	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Mesalazine—Crohn's disease	0.00097	0.00135	CcSEcCtD
Sitaxentan—Thrombocytopenia—Mesalazine—Crohn's disease	0.000969	0.00135	CcSEcCtD
Sitaxentan—Tachycardia—Mesalazine—Crohn's disease	0.000966	0.00134	CcSEcCtD
Sitaxentan—Skin disorder—Mesalazine—Crohn's disease	0.000961	0.00134	CcSEcCtD
Sitaxentan—Anorexia—Mesalazine—Crohn's disease	0.000943	0.00131	CcSEcCtD
Sitaxentan—Muscular weakness—Prednisone—Crohn's disease	0.000939	0.00131	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000939	0.00131	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000938	0.0013	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000937	0.00334	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTGER4—Crohn's disease	0.000936	0.00333	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.00093	0.00331	CbGpPWpGaD
Sitaxentan—Hypotension—Mesalazine—Crohn's disease	0.000924	0.00129	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR9—Crohn's disease	0.000907	0.00323	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TAGAP—Crohn's disease	0.000897	0.00319	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Azathioprine—Crohn's disease	0.000895	0.00124	CcSEcCtD
Sitaxentan—Insomnia—Mesalazine—Crohn's disease	0.000895	0.00124	CcSEcCtD
Sitaxentan—Somnolence—Mesalazine—Crohn's disease	0.000879	0.00122	CcSEcCtD
Sitaxentan—Dyspepsia—Mesalazine—Crohn's disease	0.000871	0.00121	CcSEcCtD
Sitaxentan—Decreased appetite—Mesalazine—Crohn's disease	0.00086	0.0012	CcSEcCtD
Sitaxentan—Body temperature increased—Azathioprine—Crohn's disease	0.000859	0.00119	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000854	0.00119	CcSEcCtD
Sitaxentan—Fatigue—Mesalazine—Crohn's disease	0.000853	0.00119	CcSEcCtD
Sitaxentan—Pain—Mesalazine—Crohn's disease	0.000846	0.00118	CcSEcCtD
Sitaxentan—Constipation—Mesalazine—Crohn's disease	0.000846	0.00118	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—GPR65—Crohn's disease	0.000843	0.003	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR6—Crohn's disease	0.000839	0.00299	CbGpPWpGaD
Sitaxentan—Weight decreased—Prednisone—Crohn's disease	0.000833	0.00116	CcSEcCtD
Sitaxentan—Hyperglycaemia—Prednisone—Crohn's disease	0.00083	0.00115	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCR9—Crohn's disease	0.000823	0.00293	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Mesalazine—Crohn's disease	0.000815	0.00113	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Prednisone—Crohn's disease	0.000809	0.00113	CcSEcCtD
Sitaxentan—Myocardial infarction—Prednisone—Crohn's disease	0.000804	0.00112	CcSEcCtD
Sitaxentan—Hypersensitivity—Azathioprine—Crohn's disease	0.0008	0.00111	CcSEcCtD
Sitaxentan—Urticaria—Mesalazine—Crohn's disease	0.000786	0.00109	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RSPO3—Crohn's disease	0.000784	0.00279	CbGpPWpGaD
Sitaxentan—Body temperature increased—Mesalazine—Crohn's disease	0.000782	0.00109	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—GPR65—Crohn's disease	0.000765	0.00273	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCR6—Crohn's disease	0.000762	0.00271	CbGpPWpGaD
Sitaxentan—Bradycardia—Prednisone—Crohn's disease	0.00075	0.00104	CcSEcCtD
Sitaxentan—Diarrhoea—Azathioprine—Crohn's disease	0.000743	0.00103	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SEL1L—Crohn's disease	0.000743	0.00265	CbGpPWpGaD
Sitaxentan—Haemoglobin—Prednisone—Crohn's disease	0.00074	0.00103	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—ACKR2—Crohn's disease	0.00074	0.00264	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PTGER4—Crohn's disease	0.000739	0.00263	CbGpPWpGaD
Sitaxentan—Haemorrhage—Prednisone—Crohn's disease	0.000737	0.00102	CcSEcCtD
Sitaxentan—Hypersensitivity—Mesalazine—Crohn's disease	0.000729	0.00101	CcSEcCtD
Sitaxentan—Dizziness—Azathioprine—Crohn's disease	0.000718	0.000999	CcSEcCtD
Sitaxentan—Asthenia—Mesalazine—Crohn's disease	0.00071	0.000987	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—MLN—Crohn's disease	0.000702	0.0025	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000698	0.00248	CbGpPWpGaD
Sitaxentan—Vomiting—Azathioprine—Crohn's disease	0.000691	0.00096	CcSEcCtD
Sitaxentan—Eye disorder—Prednisone—Crohn's disease	0.000688	0.000957	CcSEcCtD
Sitaxentan—Rash—Azathioprine—Crohn's disease	0.000685	0.000952	CcSEcCtD
Sitaxentan—Dermatitis—Azathioprine—Crohn's disease	0.000684	0.000951	CcSEcCtD
Sitaxentan—Flushing—Prednisone—Crohn's disease	0.000684	0.000951	CcSEcCtD
Sitaxentan—Headache—Azathioprine—Crohn's disease	0.00068	0.000946	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCR9—Crohn's disease	0.00068	0.00242	CbGpPWpGaD
Sitaxentan—Diarrhoea—Mesalazine—Crohn's disease	0.000677	0.000941	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PTGER4—Crohn's disease	0.000671	0.00239	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000671	0.00239	CbGpPWpGaD
Sitaxentan—Angiopathy—Prednisone—Crohn's disease	0.000668	0.00093	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000665	0.00237	CbGpPWpGaD
Sitaxentan—Immune system disorder—Prednisone—Crohn's disease	0.000665	0.000925	CcSEcCtD
Sitaxentan—Dizziness—Mesalazine—Crohn's disease	0.000654	0.00091	CcSEcCtD
Sitaxentan—Alopecia—Prednisone—Crohn's disease	0.000651	0.000905	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—GPX4—Crohn's disease	0.000648	0.00231	CbGpPWpGaD
Sitaxentan—Mental disorder—Prednisone—Crohn's disease	0.000645	0.000898	CcSEcCtD
Sitaxentan—Nausea—Azathioprine—Crohn's disease	0.000645	0.000897	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TAGAP—Crohn's disease	0.000642	0.00228	CbGpPWpGaD
Sitaxentan—Malnutrition—Prednisone—Crohn's disease	0.000641	0.000892	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GPR65—Crohn's disease	0.000632	0.00225	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL3—Crohn's disease	0.000629	0.00224	CbGpPWpGaD
Sitaxentan—Vomiting—Mesalazine—Crohn's disease	0.000629	0.000875	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000628	0.00224	CbGpPWpGaD
Sitaxentan—Rash—Mesalazine—Crohn's disease	0.000624	0.000867	CcSEcCtD
Sitaxentan—Dermatitis—Mesalazine—Crohn's disease	0.000623	0.000867	CcSEcCtD
Sitaxentan—Headache—Mesalazine—Crohn's disease	0.00062	0.000862	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000609	0.00217	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR6—Crohn's disease	0.000601	0.00214	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Prednisone—Crohn's disease	0.000595	0.000827	CcSEcCtD
Sitaxentan—Anaemia—Prednisone—Crohn's disease	0.000593	0.000824	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	0.000591	0.0021	CbGpPWpGaD
Sitaxentan—Agitation—Prednisone—Crohn's disease	0.000589	0.00082	CcSEcCtD
Sitaxentan—Nausea—Mesalazine—Crohn's disease	0.000588	0.000817	CcSEcCtD
Sitaxentan—Malaise—Prednisone—Crohn's disease	0.000578	0.000804	CcSEcCtD
Sitaxentan—Vertigo—Prednisone—Crohn's disease	0.000576	0.000801	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL3—Crohn's disease	0.000571	0.00203	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RSPO3—Crohn's disease	0.000561	0.002	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—RASGRP1—Crohn's disease	0.000553	0.00197	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCR6—Crohn's disease	0.000545	0.00194	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000542	0.000754	CcSEcCtD
Sitaxentan—Discomfort—Prednisone—Crohn's disease	0.000539	0.00075	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SEL1L—Crohn's disease	0.000532	0.00189	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PTGER4—Crohn's disease	0.000529	0.00188	CbGpPWpGaD
Sitaxentan—Oedema—Prednisone—Crohn's disease	0.000523	0.000728	CcSEcCtD
Sitaxentan—Infection—Prednisone—Crohn's disease	0.00052	0.000723	CcSEcCtD
Sitaxentan—Nervous system disorder—Prednisone—Crohn's disease	0.000513	0.000714	CcSEcCtD
Sitaxentan—Tachycardia—Prednisone—Crohn's disease	0.000511	0.00071	CcSEcCtD
Sitaxentan—Skin disorder—Prednisone—Crohn's disease	0.000508	0.000707	CcSEcCtD
Sitaxentan—Anorexia—Prednisone—Crohn's disease	0.000499	0.000694	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCR9—Crohn's disease	0.000486	0.00173	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTGER4—Crohn's disease	0.00048	0.00171	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL8—Crohn's disease	0.000479	0.0017	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000477	0.0017	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000475	0.00169	CbGpPWpGaD
Sitaxentan—Insomnia—Prednisone—Crohn's disease	0.000473	0.000658	CcSEcCtD
Sitaxentan—Dyspepsia—Prednisone—Crohn's disease	0.000461	0.000641	CcSEcCtD
Sitaxentan—Decreased appetite—Prednisone—Crohn's disease	0.000455	0.000633	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GPR65—Crohn's disease	0.000452	0.00161	CbGpPWpGaD
Sitaxentan—Fatigue—Prednisone—Crohn's disease	0.000451	0.000628	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—IL3—Crohn's disease	0.00045	0.0016	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCR6—Crohn's disease	0.00045	0.0016	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.00045	0.0016	CbGpPWpGaD
Sitaxentan—Constipation—Prednisone—Crohn's disease	0.000448	0.000622	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2RA—Crohn's disease	0.000441	0.00157	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000436	0.00155	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000433	0.00154	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Prednisone—Crohn's disease	0.000431	0.0006	CcSEcCtD
Sitaxentan—Urticaria—Prednisone—Crohn's disease	0.000416	0.000578	CcSEcCtD
Sitaxentan—Body temperature increased—Prednisone—Crohn's disease	0.000414	0.000575	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—IL3—Crohn's disease	0.000409	0.00146	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RBX1—Crohn's disease	0.000407	0.00145	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000407	0.00145	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL2RA—Crohn's disease	0.0004	0.00143	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTGER4—Crohn's disease	0.000396	0.00141	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—RASGRP1—Crohn's disease	0.000396	0.00141	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	0.00039	0.00139	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Prednisone—Crohn's disease	0.000386	0.000536	CcSEcCtD
Sitaxentan—Asthenia—Prednisone—Crohn's disease	0.000376	0.000522	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000371	0.00132	CbGpPWpGaD
Sitaxentan—Diarrhoea—Prednisone—Crohn's disease	0.000358	0.000498	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—UBE2D1—Crohn's disease	0.000357	0.00127	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RIPK2—Crohn's disease	0.000346	0.00123	CbGpPWpGaD
Sitaxentan—Dizziness—Prednisone—Crohn's disease	0.000346	0.000481	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000346	0.00123	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL8—Crohn's disease	0.000342	0.00122	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000341	0.00121	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL3—Crohn's disease	0.000338	0.0012	CbGpPWpGaD
Sitaxentan—Vomiting—Prednisone—Crohn's disease	0.000333	0.000463	CcSEcCtD
Sitaxentan—Rash—Prednisone—Crohn's disease	0.00033	0.000459	CcSEcCtD
Sitaxentan—Dermatitis—Prednisone—Crohn's disease	0.00033	0.000459	CcSEcCtD
Sitaxentan—Headache—Prednisone—Crohn's disease	0.000328	0.000456	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RASGRP1—Crohn's disease	0.000327	0.00116	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCR6—Crohn's disease	0.000322	0.00115	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2RA—Crohn's disease	0.000316	0.00112	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000315	0.00112	CbGpPWpGaD
Sitaxentan—Nausea—Prednisone—Crohn's disease	0.000311	0.000432	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—JAK2—Crohn's disease	0.000296	0.00105	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SOCS1—Crohn's disease	0.000296	0.00105	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RBX1—Crohn's disease	0.000291	0.00104	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2RA—Crohn's disease	0.000287	0.00102	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTGER4—Crohn's disease	0.000284	0.00101	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—TYK2—Crohn's disease	0.000282	0.001	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL8—Crohn's disease	0.00027	0.000963	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000269	0.000959	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—JAK2—Crohn's disease	0.000269	0.000958	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—UBE2D1—Crohn's disease	0.000256	0.00091	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SMAD3—Crohn's disease	0.000255	0.000909	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000252	0.000898	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RIPK2—Crohn's disease	0.000248	0.000882	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000246	0.000874	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL8—Crohn's disease	0.000246	0.000874	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL3—Crohn's disease	0.000242	0.00086	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2RA—Crohn's disease	0.000236	0.000842	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RASGRP1—Crohn's disease	0.000234	0.000832	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.00023	0.000819	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—JAK2—Crohn's disease	0.000212	0.000755	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SOCS1—Crohn's disease	0.000212	0.000754	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TYK2—Crohn's disease	0.000202	0.000719	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—Crohn's disease	0.000194	0.000689	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—JAK2—Crohn's disease	0.000193	0.000686	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SMAD3—Crohn's disease	0.000183	0.000651	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLA2G4F—Crohn's disease	0.000181	0.000645	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—Crohn's disease	0.000176	0.000626	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2RA—Crohn's disease	0.000169	0.000603	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TYK2—Crohn's disease	0.000167	0.000593	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	0.000165	0.000588	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—JAK2—Crohn's disease	0.000159	0.000566	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTMR3—Crohn's disease	0.000154	0.000548	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—Crohn's disease	0.000145	0.000516	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTMR3—Crohn's disease	0.00014	0.0005	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—Crohn's disease	0.000138	0.000491	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—FADS1—Crohn's disease	0.00012	0.000427	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TYK2—Crohn's disease	0.000119	0.000425	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—Crohn's disease	0.000117	0.000415	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—JAK2—Crohn's disease	0.000114	0.000405	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPX4—Crohn's disease	0.000112	0.0004	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—FADS1—Crohn's disease	0.000109	0.000389	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	0.000109	0.000388	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GCKR—Crohn's disease	0.000108	0.000386	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—Crohn's disease	0.000104	0.00037	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPX4—Crohn's disease	0.000102	0.000365	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GCKR—Crohn's disease	9.89e-05	0.000352	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—Crohn's disease	9.87e-05	0.000351	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTMR3—Crohn's disease	9.26e-05	0.00033	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—Crohn's disease	8.35e-05	0.000297	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—Crohn's disease	8.15e-05	0.00029	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	7.75e-05	0.000276	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—FADS1—Crohn's disease	7.21e-05	0.000257	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	7.07e-05	0.000252	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	6.78e-05	0.000241	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPX4—Crohn's disease	6.76e-05	0.00024	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GCKR—Crohn's disease	6.52e-05	0.000232	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	6.19e-05	0.00022	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—Crohn's disease	5.83e-05	0.000208	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—Crohn's disease	3.45e-05	0.000123	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—Crohn's disease	3.15e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—Crohn's disease	3.02e-05	0.000108	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—Crohn's disease	2.75e-05	9.81e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—Crohn's disease	2.08e-05	7.39e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.82e-05	6.47e-05	CbGpPWpGaD
